These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits
| Thyroid monitoring and management | Important safety considerations | Frequently asked questions | Take home message You can take Wegovy (semaglutide) if you have an underactive thyroid (hypothyroidism) and your BMI is over 27
Substance Powder-based semaglutide Development phase Preclinical Temperature stability 1 0.1% degradation after 6 months 2 Administration Nasal powder (other delivery routes are explored) Leverage established manufacturing processes Spray-drying process (intranasal delivery) Partnership Seeking partnership for continued research and development Demonstrating strong preclinical performance A preclinical in-vivo study evaluated three powder-based intranasal semaglutide formulations developed with AmorphOX
adults 33 million people- are currently taking GLP-1s
Down Syndrome
Our experience shows that a well-planned off-cycle is just as critical as the on-cycle